Legacy Impact: The Artemisia annua Breeding Project

Our long-term research into the medicinal crop Artemisia annua serves as an international benchmark for how fundamental biochemical genetics can solve global humanitarian crises. By characterising and genetically mapping the traits responsible for producing the sesquiterpene artemisinin—the core component of ACTs (Artemisinin-based Combination Therapies)—our laboratory developed high-yielding, non-GM F1 hybrids.

A standout among these was a robust, high-biomass variety optimised for leaf-artemisinin concentration, which was grown commercially in Africa for three years under the designation Hyb8001r. In a major milestone, this variety successfully cleared the rigorous Chinese regulatory approval process to achieve formal registration in China—the indigenous home of traditional artemisinin production. Securing this registration required navigating two years of extensive, independent field trials benchmarked against established Chinese varieties.

Reflecting this cross-border success, the hybrid was officially registered under the Chinese name 药客佳蒿1号 (pronounced YaoKe JiaHao YiHao). The name is a deliberate phonetic play on "York" ("YaoKe" translates to "Medicine People"), while the remaining characters designate it as "Good Artemisia variety, number one in the series."
Distributed globally in partnership with the Bill & Melinda Gates Foundation, these elite hybrids helped stabilise the global supply chain and reduced the cost of life-saving anti-malarial treatments, enabling the delivery of over 60 million treatments worldwide. While active molecular breeding programs for Artemisia have concluded, the genomic tools, assemblies, and trichome-specific metabolic insights generated by this work continue to inform our evolutionary modelling, macro-genomic analyses, and metabolic engineering approaches across all other medicinal species currently under investigation.

Publications

• Graham, I.A., Besser, K., Blumer, S., Branigan, C.A., Czechowski, T., Elias, L., Guterman, I., Harvey, D., Isaac, P.G., Khan, A.M., Larson, T.R., Li, Y., Owens, S., Pawson, T., Penfield, T., Rae, A.M., Rathbone, D.A., Ross, J., Smallwood, M.F., Segura, V., Townsend, T., Vyas, D., Winzer, T., Bowles, D. (2010). The genetic map of Artemisia annua L. identifies multiple loci affecting yield of the antimalarial drug artemisinin. Science, 327: 328-331.
• Czechowski, T., Larson, T.R., Catania, T.M., Harvey, D., Brown, G.D. and Graham, I.A. (2016). Artemisia annua mutant impaired in artemisinin synthesis demonstrates importance of nonenzymatic conversion in terpenoid metabolism. Proceedings of the National Academy of Sciences USA, 113: 15150-15155.
• Liao, B., Shen, X., Xiang, L., Guo, S., Chen, S., Meng, Y., Liang, Y., Ding, D., Bai, J., Zhang, D., Czechowski, T., Li, Y., Yao, H., Ma, T., Howard, C., Sun, C., Liu, J., Pei, J., Gao, J., Wang, J., Qiu, X., Huang, Z., Li, H., Yuan, L., Wei, J., Graham, I.A., Xu, J., Zhang, B., Chen, S. (2022). Allele-aware chromosome-level genome assembly of Artemisia annua reveals the correlation between ADS expansion and artemisinin yield. Molecular Plant, 15: 1310-1328.

The CNAP Artemisia Research Project was initiated in 2006 with core funding from The Bill & Melinda Gates Foundation to develop improved varieties of Artemisia annua dedicated to securing the global ACT supply chain. The project and related genomics research was directed by Professor Ian Graham (2006–present) and was co-directed by Professor Dianna Bowles (2006–2012, now Emeritus).